{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T15:09:57Z","timestamp":1774969797968,"version":"3.50.1"},"reference-count":38,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T00:00:00Z","timestamp":1774915200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Background\/Objectives: Diffuse large B-cell lymphoma (DLBCL) and high-grade follicular lymphoma (FL) are aggressive B-cell malignancies predominantly affecting older adults. R-CHOP remains the frontline standard of care, with frail and elderly patients requiring attenuated regimens such as R-mini-CHOP. Real-world comparative data in elderly and Hispanic populations remain limited. We aimed to evaluate outcomes of R-mini-CHOP versus R-CHOP in elderly patients and to explore potential differences by ethnicity. Methods: Single-center retrospective analysis of adult patients older than 70 years with DLBCL and high-grade FL, treated between January 2014 and June 2025. Clinical characteristics, treatment responses, and survival outcomes were analyzed. The overall survival (OS) and progression-free survival (PFS) were estimated using the Kaplan\u2013Meier method. Results: A total of 136 patients were included (72 R-mini-CHOP; 64 R-CHOP). Patients receiving R-mini-CHOP were older (median 82 vs. 74 years) and had higher-risk features. Overall response rates were 88.7% and 92.6% in the R-mini-CHOP and R-CHOP groups, respectively. Two-year OS was 79.3% for R-mini-CHOP and 76.7% for R-CHOP. Median OS and PFS were not reached in either group. Elevated lactate dehydrogenase (LDH) was associated with an inferior response. We identified a trend toward better response with R-CHOP in Hispanic patients, although this was not statistically significant. Conclusions: In this real-world cohort, R-mini-CHOP achieved response and survival outcomes comparable to R-CHOP despite worse baseline characteristics. These findings support the use of dose-attenuated therapy in frail and elderly patients and suggest that equitable access to care may mitigate ethnic disparities in outcomes.<\/jats:p>","DOI":"10.3390\/cancers18071124","type":"journal-article","created":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T13:23:17Z","timestamp":1774963397000},"page":"1124","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Real-World Data of R-mini-CHOP Therapy in Elderly Hispanic Population with Diffuse Large B-Cell Lymphoma and High-Grade Follicular Lymphoma"],"prefix":"10.3390","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-8176-2342","authenticated-orcid":false,"given":"Carla","family":"Romagnoli","sequence":"first","affiliation":[{"name":"Division of Hematology\/Oncology, Mount Sinai Medical Center, Miami Beach, FL 33140, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4219-7708","authenticated-orcid":false,"given":"Veronica","family":"Guerra","sequence":"additional","affiliation":[{"name":"Department of Hematology, Washington University School of Medicine, St. Louis, MO 63310, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leily","family":"Santos-Carrion","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, Mount Sinai Medical Center, Miami Beach, FL 33140, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marisol","family":"Ocampo","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, Mount Sinai Medical Center, Miami Beach, FL 33140, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandra","family":"Lyubimova","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, Mount Sinai Medical Center, Miami Beach, FL 33140, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Evelyn","family":"Goya Balaguer","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, Mount Sinai Medical Center, Miami Beach, FL 33140, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yelida","family":"Brauchle","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, Mount Sinai Medical Center, Miami Beach, FL 33140, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oleg","family":"Gligich","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, Mount Sinai Medical Center, Miami Beach, FL 33140, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruno","family":"Bastos","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, Mount Sinai Medical Center, Miami Beach, FL 33140, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8273-7636","authenticated-orcid":false,"given":"Aron","family":"Simkins","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, Mount Sinai Medical Center, Miami Beach, FL 33140, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arnold","family":"Blaustein","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, Mount Sinai Medical Center, Miami Beach, FL 33140, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Schwartz","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, Mount Sinai Medical Center, Miami Beach, FL 33140, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5983-980X","authenticated-orcid":false,"given":"Mike","family":"Cusnir","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, Mount Sinai Medical Center, Miami Beach, FL 33140, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6018-5535","authenticated-orcid":false,"given":"Jacqueline C.","family":"Barrientos","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, Mount Sinai Medical Center, Miami Beach, FL 33140, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2026,3,31]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"e840","DOI":"10.1016\/S2352-3026(21)00241-6","article-title":"A comprehensive approach to therapy of haematological malignancies in older patients","volume":"8","author":"Cordoba","year":"2021","journal-title":"Lancet Haematol."},{"key":"ref_2","unstructured":"National Cancer Institute (2026, March 27). Surveillance, Epidemiology, and End Results (SEER) Data, Available online: https:\/\/seer.cancer.gov\/."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"268","DOI":"10.3109\/10428194.2012.708751","article-title":"Examining racial differences in diffuse large B-cell lymphoma presentation and survival","volume":"54","author":"Flowers","year":"2012","journal-title":"Leuk. Lymphoma"},{"key":"ref_4","unstructured":"Lugtenburg, P.J., and Mutsaers, P.G.N.J. (2026, March 27). How I Treat Older Patients with DLBCL in the Frontline Setting. Available online: http:\/\/ashpublications.org\/blood\/article-pdf\/141\/21\/2566\/2053032\/blood_bld-2020-008239-c-main.pdf."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Arcari, A., Cavallo, F., Puccini, B., and Vallisa, D. (2023). New treatment options in elderly patients with Diffuse Large B-cell Lymphoma. Front. Oncol., 13.","DOI":"10.3389\/fonc.2023.1214026"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"102812","DOI":"10.1016\/j.canep.2025.102812","article-title":"Are oldest old patients with diffuse large B-cell lymphoma different than their younger counterparts: Results from the REALYSA real-life cohort","volume":"96","author":"Cantrelle","year":"2025","journal-title":"Cancer Epidemiol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2530","DOI":"10.1002\/cncr.25765","article-title":"Racial differences in the presentation and outcomes of diffuse large B-cell lymphoma in the United States","volume":"117","author":"Shenoy","year":"2010","journal-title":"Cancer"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"5450","DOI":"10.1182\/blood-2025-5450","article-title":"Comparative effectiveness of R-minichop versus R-CHOP in older patients with diffuse large B-cell lymphoma: A propensity score-matched analysis from a real-world grupo de estudio latinoamericano de linfoproliferativos (GELL) cohort","volume":"146","author":"Martinez","year":"2025","journal-title":"Blood"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1182\/blood-2023-187049","article-title":"Real-World Data on the Clinical Features, Therapy Patterns and Outcomes of 651 Elderly Patients with Diffuse Large B-Cell Lymphoma in Latin America: A Study from the Grupo De Estudio Latinoamericano De Linfoproliferativos (GELL)","volume":"142","author":"Candelaria","year":"2023","journal-title":"Blood"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1080\/10428194.2020.1839656","article-title":"Racial and ethnic differences in diffuse large B-cell lymphoma survival among an underserved, urban population","volume":"62","author":"Blansky","year":"2020","journal-title":"Leuk. Lymphoma"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1080\/10428194.2021.1975188","article-title":"Epidemiology of diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) in the United States and Western Europe: Population-level projections for 2020\u20132025","volume":"63","author":"Kanas","year":"2021","journal-title":"Leuk. Lymphoma"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1093\/gerona\/glt162","article-title":"Heterogeneity in Healthy Aging","volume":"69","author":"Lowsky","year":"2013","journal-title":"J. Gerontol. Ser. A"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"398","DOI":"10.5603\/OCP.2023.0021","article-title":"Comprehensive geriatric assessment and clinical outcomes of frail older adults with diffuse large B-cell lymphoma: A meta-analysis","volume":"19","author":"Oscanoa","year":"2023","journal-title":"Oncol. Clin. Pract."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Li, Z., Lin, Y., Shi, Y., Yang, T., An, L., Qi, Y., Zhang, P., Huang, X., Su, X., and Deng, Y. (2025). Association between malnutrition diagnosed by different screening and assessment tools and clinical outcomes: An umbrella review. Front. Nutr., 12.","DOI":"10.3389\/fnut.2025.1676201"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"3165","DOI":"10.1007\/s00277-024-05850-5","article-title":"Quality of life assessment in diffuse large B-cell lymphoma (DLBCL) in REFLECT: A prospective, non-interventional, multicenter, German study, assessing Sandoz rituximab in combination with CHOP","volume":"103","author":"Kubuschok","year":"2024","journal-title":"Ann. Hematol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1007\/s00280-019-03775-9","article-title":"Cyclophosphamide dose adjustment based on body weight and albuminemia in elderly patients treated with R-mini-CHOP","volume":"83","author":"Baudry","year":"2019","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1182\/bloodadvances.2025017530","article-title":"Inclusion, characteristics, and reporting of older patients in recent registration trials for DLBCL","volume":"10","author":"Neuendorff","year":"2026","journal-title":"Blood Adv."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1200\/JCO.20.02465","article-title":"Simplified Geriatric Assessment in Older Patients With Diffuse Large B-Cell Lymphoma: The Prospective Elderly Project of the Fondazione Italiana Linfomi","volume":"39","author":"Merli","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"921","DOI":"10.3109\/10428194.2014.953142","article-title":"Comprehensive geriatric assessment is an essential tool to support treatment decisions in elderly patients with diffuse large B-cell lymphoma: A prospective multicenter evaluation in 173 patients by the Lymphoma Italian Foundation (FIL)","volume":"56","author":"Tucci","year":"2014","journal-title":"Leuk. Lymphoma"},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Wang, Y., Ren, X., Huang, K., Liang, X., Pu, L., Hu, L., and Zhai, Z. (2023). Comparison of first-line treatments for elderly patients with diffuse large B-cell lymphoma: A systematic review and network meta-analysis. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.1082293"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.3324\/haematol.2011.050617","article-title":"The proportion of activated B-cell like subtype among de novo diffuse large B-cell lymphoma increases with age","volume":"96","author":"Mareschal","year":"2011","journal-title":"Haematologica"},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Lage, L.A.d.P.C., De Vita, R.N., Alves, L.B.d.O., Jacomassi, M.D., Culler, H.F., Reichert, C.O., de Freitas, F.A., Rocha, V., Siqueira, S.A.C., and Costa, R.d.O. (2024). Predictors of Survival, Treatment Modalities, and Clinical Outcomes of Diffuse Large B-Cell Lymphoma in Patients Older Than 70 Years Still an Unmet Medical Need in 2024 Based on Real-World Evidence. Cancers, 16.","DOI":"10.3390\/cancers16081459"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1182\/blood.V116.21.853.853","article-title":"Rituximab and Reduced Dose CHOP (R-mini-CHOP) for Patients Over 80 Years with Diffuse Large B-Cell Lymphoma (DLBCL)\u2014Groupe d\u2019Etude Des Lymphomes De l\u2019Adulte (GELA) Study LNH03-7B","volume":"116","author":"Peyrade","year":"2010","journal-title":"Blood"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/S1470-2045(11)70069-9","article-title":"Attenuated immunochemotherapy regimen (R-miniCHOP) in elderly patients older than 80 years with diffuse large B-cell lymphoma: A multicentre, single-arm, phase 2 trial","volume":"12","author":"Peyrade","year":"2011","journal-title":"Lancet Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1007\/s11864-018-0565-6","article-title":"Treating Diffuse Large B Cell Lymphoma in the Very Old or Frail Patients","volume":"19","author":"Kumar","year":"2018","journal-title":"Curr. Treat. Options Oncol."},{"key":"ref_26","first-page":"216","article-title":"R-miniCHOP versus R-CHOP in elderly patients with diffuse large B-cell lymphoma: A propensity matched population-based study","volume":"99","author":"Brink","year":"2023","journal-title":"Am. J. Hematol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2426","DOI":"10.1182\/bloodadvances.2021004665","article-title":"Impact of R-CHOP dose intensity on survival outcomes in diffuse large B-cell lymphoma: A systematic review","volume":"5","author":"Bataillard","year":"2021","journal-title":"Blood Adv."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"102185","DOI":"10.1016\/j.jgo.2025.102185","article-title":"Association of age and performance status with adverse events in older adults with diffuse large B-cell lymphoma receiving frontline R-CHOP therapy: Alliance 151930, a secondary analysis of the phase III trial CALGB 50303","volume":"16","author":"Morrison","year":"2025","journal-title":"J. Geriatr. Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.clml.2012.11.002","article-title":"Zoledronic Acid for Prevention of Bone Loss in Patients Receiving Primary Therapy for Lymphomas: A Prospective, Randomized Controlled Phase III Trial","volume":"13","author":"Westin","year":"2013","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1056\/NEJMoa2115304","article-title":"Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma","volume":"386","author":"Tilly","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"3698","DOI":"10.1200\/JCO-25-00925","article-title":"Five-Year Outcomes of the POLARIX Study Comparing Pola-R-CHP and R-CHOP in Patients With Diffuse Large B-Cell Lymphoma","volume":"43","author":"Morschhauser","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.1182\/bloodadvances.2024014707","article-title":"Subgroup analysis of older patients \u2265 60 years with diffuse large B-cell lymphoma in the phase 3 POLARIX study","volume":"9","author":"Hu","year":"2025","journal-title":"Blood Adv."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"3698","DOI":"10.1182\/blood-2025-3698","article-title":"Polatuzumab vedotin plus R-CHP demonstrates high efficacy with manageable toxicity in treatment-Na\u00efve dual-expressor DLBCL (DEL): Real-world analysis with focus on elderly high-risk patients","volume":"146","author":"Ren","year":"2025","journal-title":"Blood"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1182\/blood-2025-784","article-title":"Real-world outcomes of frontline polatuzumab-rchp and impact of frailty in older adults with diffuse large B-cell lymphoma","volume":"146","author":"Iyengar","year":"2025","journal-title":"Blood"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"7822","DOI":"10.1182\/blood-2024-205048","article-title":"Efficacy and Safety of R-Mini-CHP Administered in Combination with Polatuzumab Vedotin (Pola-R-mini-CHP) in Patients \u2265 80 Years Old with Diffuse Large B-Cell Lymphoma in the Real-World Setting: A Single-Institute Retrospective Study","volume":"144","author":"Sekiguchi","year":"2024","journal-title":"Blood"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"5470","DOI":"10.1182\/blood-2025-5470","article-title":"Efficacy and safety of polatuzumab vedotin-based regimens for elderly\/frail DLBCL patients: A real-world study","volume":"146","author":"Liu","year":"2025","journal-title":"Blood"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"2575","DOI":"10.1182\/bloodadvances.2022008643","article-title":"Racial and socioeconomic disparities in CLL\/SLL: Analysis of SEER data from 2006 to 2019","volume":"7","author":"Kittai","year":"2023","journal-title":"Blood Adv."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"e70032","DOI":"10.1002\/cam4.70032","article-title":"Association of race\/ethnicity and insurance with survival in patients with diffuse large B-cell lymphoma in a large real-world cohort","volume":"13","author":"Jin","year":"2024","journal-title":"Cancer Med."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/7\/1124\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T13:40:56Z","timestamp":1774964456000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/7\/1124"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,31]]},"references-count":38,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2026,4]]}},"alternative-id":["cancers18071124"],"URL":"https:\/\/doi.org\/10.3390\/cancers18071124","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,31]]}}}